RxDoctor Payments Data

Prita Madkaiker, MD

Internal Medicine · Jacksonville, FLNPI 1508832361

Payments from drug & device makers

$8,239in general payments, 2019–2025

Across 369 payments — averaging $22.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$1K
  • AbbVie$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$975
  • Axsome Therapeutics, Inc.$811
  • Takeda Pharmaceuticals U.S.A., Inc.$707
  • Otsuka America Pharmaceutical, Inc.$684
  • plus $3K from 23 others

What the payments were for

  • Food & beverage$8,239100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,239 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$33,369
Medicare patients
64
Services billed
407

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide82$94,214
LinzessLinaclotide16$20,061
JanuviaSitagliptin Phosphate19$13,689
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl89$12,644
XareltoRivaroxaban13$7,326
Omeprazole72$1,322
Lidocaine15$1,281
Ondansetron Hcl35$1,141
Albuterol Sulfate HfaAlbuterol Sulfate48$1,128
Wixela InhubFluticasone Propion/Salmeterol17$909
Fluticasone Propionate67$830
Levothyroxine Sodium93$821
Atorvastatin Calcium98$816
Gabapentin31$780
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen15$735

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$173$94,21482 claims
AbbVieLinzess$1,062$20,06116 claims
Johnson & JohnsonXarelto$155$7,32613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →